Evidence map›Paper›PMID 35201447›Full record

ArticleDiscover oncology2021

Attitudes among dermatologists regarding non-melanoma skin cancer treatment options.

Luca Fania, Tonia Samela, Gaia Moretta, Francesco Ricci, Elena Dellambra, Mara Mancini, Francesca Sampogna, Annarita Panebianco, Damiano Abeni

Open access · goldAbstract read
In one paragraph

Article in Discover oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Luca Fania *IDI-IRCCS, Dermatological Research Hospital, Via dei Monti di Creta 104, 00167, Rome, Italy. l.fania@idi.it.
Tonia Samela *IDI-IRCCS, Dermatological Research Hospital, Via dei Monti di Creta 104, 00167, Rome, Italy.
Gaia MorettaIDI-IRCCS, Dermatological Research Hospital, Via dei Monti di Creta 104, 00167, Rome, Italy.
Francesco RicciIDI-IRCCS, Dermatological Research Hospital, Via dei Monti di Creta 104, 00167, Rome, Italy.
Elena DellambraIDI-IRCCS, Dermatological Research Hospital, Via dei Monti di Creta 104, 00167, Rome, Italy.
Mara ManciniIDI-IRCCS, Dermatological Research Hospital, Via dei Monti di Creta 104, 00167, Rome, Italy.
Francesca SampognaIDI-IRCCS, Dermatological Research Hospital, Via dei Monti di Creta 104, 00167, Rome, Italy.
Annarita PanebiancoIDI-IRCCS, Dermatological Research Hospital, Via dei Monti di Creta 104, 00167, Rome, Italy.
Damiano AbeniIDI-IRCCS, Dermatological Research Hospital, Via dei Monti di Creta 104, 00167, Rome, Italy.
Istituto Dermopatico dell'Immacolata · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-melanoma skin cancers include basal and squamous cell carcinoma. These tumors have become an important health issue for their high incidence and for the morbidity, especially if untreated for a long period. Over the last 20 years, therapeutic approaches for these tumours have been improved and tailored. In this survey we provided data from one hundred and ten Italian dermatologists regarding knowledge and attitude towards different therapeutic approaches on non-melanoma skin cancers. In our study, we observed that surgery and imiquimod 5% cream were the most used treatment by dermatologists for basal cell carcinoma, while, surgery was the most common treatment for cutaneous squamous cell carcinoma. Furthermore, we observed some differences regarding the prescribed therapies in the different Italian geographical areas (i.e., Mohs' surgery and electrochemotherapy were more frequently used in Northern compared to Central and Southern Italy whereas immunotherapy was more used in Southern compared to Northern and Central Italy) and even considering the year of specialization of the dermatologists (i.e., immunotherapy with cemiplimab was prescribed mainly by dermatologists with 10-19 years of specialization). However, for locally advanced and metastatic forms of basal and squamous cell carcinoma, Hedgehog Pathway Inhibitors and anti- Programmed cell death protein antibody treatment, respectively, were used in line with the newest evolution of therapies regarding this topic. Considering the importance of skin cancers and its progressive increase in incidence, it is crucial to improve the knowledge of different therapeutic approaches among dermatologists.

Indexed as

Basal cell carcinomaNon-melanomaSkin cancerSquamous cell carcinomaTherapy

Identifiers

PMID35201447
PMCPMC8777506
OpenAlexW3198550744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.